Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.

Adiponectin has antiatherogenic properties and attenuates endothelial inflammatory responses. CD146 is a novel cell adhesion molecule localized at the endothelial junction. In renal failure, endothelial dysfunction and atherosclerosis are almost universal. We studied possible correlations between adiponectin, CD146, and other markers of endothelial cell injury in patients with chronic renal failure (CRF) on conservative treatment and patients with and without diabetic nephropathy maintained on chronic ambulatory peritoneal dialysis (CAPD). We assessed adiponectin, tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor (PAI-1), thrombin-activatable fibrinolysis inhibitor, and endothelial function/injury markers: von Willebrand factor, thrombomodulin, vascular cell adhesion molecule (VCAM), intercellular adhesion molecule, and CD146. Adiponectin was elevated in patients with CRF and on CAPD. It correlated significantly, with PAI-1, thrombin-activatable fibrinolysis inhibitor, intercellular adhesion molecule, VCAM, and CD146 in nondiabetics on CAPD. In diabetics, CAPD adiponectin correlated positively with C146 and VCAM and negatively with PAI and TFPI. In multivariate regression analysis, only CD146 remained a positive predictor of adiponectin in all CAPD patients. In CRF, adiponectin correlated with CD146. In healthy volunteers, adiponectin correlated with TFPI and CD146. Elevated adiponectin related to CD146 may be the expression of a counterregulatory response aimed at mitigating the consequences in endothelial damage and increased cardiovascular risk in renal failure.

[1]  J. Małyszko,et al.  Endothelial Cell Injury Markers in Chronic Renal Failure on Conservative Treatment and Continuous Ambulatory Peritoneal Dialysis , 2004, Kidney and Blood Pressure Research.

[2]  A. Xu,et al.  Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. , 2004, The Journal of clinical endocrinology and metabolism.

[3]  A. Le Bivic,et al.  Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. , 2001, Blood.

[4]  G. Boltz‐Nitulescu,et al.  Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. , 2003, Biochemical and biophysical research communications.

[5]  J. Małyszko,et al.  Comparison of Hemostatic Disturbances between Patients on Capd and Patients on Hemodialysis , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[6]  R. Nagai,et al.  Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. , 2004, Biochemical and biophysical research communications.

[7]  S. Kihara,et al.  Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. , 2003, Kidney international. Supplement.

[8]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[9]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  S. Kihara,et al.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. , 2000, Blood.

[11]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[12]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[13]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[14]  N. Yorioka,et al.  Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. , 1997, Nephron.

[15]  T. Funahashi,et al.  Plasma adiponectin concentration before and after successful kidney transplantation. , 2003, Transplantation proceedings.

[16]  J. Woo,et al.  Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. , 2003, Journal of the American Society of Nephrology : JASN.

[17]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[18]  J. Sampol,et al.  S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. , 1996, Tissue antigens.

[19]  J. Johnson,et al.  MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. , 1997, Journal of immunology.

[20]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[21]  T. Funahashi,et al.  Hypoadiponectinemia is closely linked to endothelial dysfunction in man. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[23]  大内 乗有.  Novel modulator for endothelial adhesion molecules : Adipocyte-derived plasma protein adiponectin , 2001 .

[24]  S. Kihara,et al.  Erratum , 2003, Heart.

[25]  J. Fernández-Real,et al.  Adiponectin is associated with vascular function independent of insulin sensitivity. , 2004, Diabetes care.

[26]  T. Funahashi,et al.  Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina , 2004, Thrombosis and Haemostasis.

[27]  M. Kakei,et al.  Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. , 2004, Biochemical and biophysical research communications.

[28]  R. Wolfe,et al.  A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[29]  G. Hotamisligil.  The role of TNFα and TNF receptors in obesity and insulin resistance , 1999 .

[30]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[31]  S. Kihara,et al.  Adiponectin in essential hypertension. , 2002, Journal of nephrology.

[32]  T. Ogihara,et al.  Association of Hypoadiponectinemia With Impaired Vasoreactivity , 2003, Hypertension.

[33]  J. Wauters,et al.  Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[34]  P. Stenvinkel,et al.  Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. , 2004, Kidney international.

[35]  T Nakamura,et al.  An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[36]  R. Knöfler,et al.  Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. , 1994, Thrombosis research.

[37]  T. Shigematsu,et al.  Is Atherosclerosis Accelerated by Capd? , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[38]  P. Brunet,et al.  Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration , 2003, Thrombosis and Haemostasis.

[39]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[40]  A. Więcek,et al.  Decreased plasma concentration of a novel anti-inflammatory protein--adiponectin--in hypertensive men with coronary artery disease. , 2003, Thrombosis research.

[41]  P. Stenvinkel,et al.  Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. , 2003, Journal of the American Society of Nephrology : JASN.

[42]  B. Scribner,et al.  Accelerated atherosclerosis in prolonged maintenance hemodialysis. , 1974, The New England journal of medicine.

[43]  M. Davies,et al.  The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis , 1993, The Journal of pathology.